Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor ...

Vir Biotechnology (VIR) “announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in ...

Statin use significantly improved OS for men with metastatic hormone-sensitive and nonmetastatic castrate-resistant prostate ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At week 24, LPCN 1148 significantly improved the ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

The pooled cohort analysis published in the July issue of The Lancet Oncology by Katie O’Brien and colleagues provides important new insight into the relationship between hormone therapy and breast ...

Investing.com -- Vir Biotechnology Inc (NASDAQ:VIR) stock rose 4.3% Thursday after the company announced it has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating VIR-5500 in ...

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend ...